Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: So here is a question I've seen asked many times. It's one that now has....

trial attorney? You said:"There is a risk anytime you go to trial so us trial attorneys have to evaluate that risk everytime and compare it with whatever settlement is on the table."

I have a couple questions from your post. You said:

"Even a lump sum buyout can be spread over several payments."

With our current revenue recognition policy how would several payments have any impact on the 10Q numbers? If the policy has changed without our knowledge, wouldn't you find the lifting of the trading ban disturbing knowing that share purchases by insiders are on our backs by way of lost equity?

Also you say: "Further, nothing in the letter is contrary to the USTPO/contingency theory...."

My question would be: How do you interpret 8K Items 2.03 and 2.04 as it may relate to the reporting responsibilities of the J's or any licensees that would have such a contingency? TIA,joe







Share
New Message
Please login to post a reply